Prostate cancer: molecular biology of early progression to androgen independence

M D Sadar1, M Hussain, N Bruchovsky

  • 1Department of Cancer Endocrinology, British Columbia Cancer Agency, Vancouver, Canada. msadar@bccancer.bc.ca

Insights

Androgen independence in prostate cancer may stem from increased protein kinase A (PKA) activity, enhancing androgen receptor function without androgen. Targeting this pathway offers new therapeutic strategies for advanced prostate cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Endocrinology

Background:

  • Prostate cancer progression involves androgen independence and metastasis.
  • Androgen independence is a key challenge in prostate cancer therapy.
  • Early detection of progression is possible via prostate-specific antigen (PSA) response.

Purpose of the Study:

  • Investigate the molecular mechanisms of androgen independence in prostate cancer.
  • Identify potential therapeutic targets to prevent or delay androgen independence.
  • Explore the role of the androgen receptor and cAMP-dependent protein kinase (PKA) pathway.

Main Methods:

  • Studied the molecular biology of PSA gene regulation.
  • Examined ligand-independent activation of the androgen receptor.
  • Investigated the involvement of the PKA signal transduction pathway.
  • Assessed the effect of anti-androgens like bicalutamide.

Main Results:

  • Ligand-independent androgen receptor activation is implicated in androgen independence.
  • Increased PKA activity enhances androgen receptor binding to PSA gene elements in the absence of androgen.
  • The amino-terminus of the androgen receptor is involved in PKA-mediated activation.
  • The anti-androgen bicalutamide can counteract this effect.

Conclusions:

  • Targeting the PKA-activated androgen receptor pathway presents a novel therapeutic strategy.
  • Decoy molecules or agents inhibiting PKA could prevent or delay androgen independence.
  • Further research into nuclear-accessible agents is warranted for prostate cancer treatment.

Related Concept Videos

Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K